Hepatitis B Vaccine Market

Hepatitis B Vaccine Market Analysis

The Hepatitis B Vaccine Market size is estimated at USD 8.5 billion in 2025, and is expected to reach USD 11.54 billion by 2030, at a CAGR of 6.30% during the forecast period (2025-2030).

Hepatitis B is a viral infection of the liver, which can cause cirrhosis and hepatocellular carcinoma. Key drivers supporting market development include growing prevalence, government-led immunization programs, heightened public awareness, and technological innovations. For instance, in November 2024, the Government of India highlighted the success of its Universal Immunization Programme (UIP). This flagship public health initiative played a pivotal role in slashing the under-5 mortality rate from 45 per 1000 live births in 2014 to 32 per 1000 live births by 2020. UIP offers complimentary immunizations against 12 diseases, including Hepatitis B. Similar initiatives by other economies are expected to strengthen the market expansion over the projected period.

Furthermore, technological innovations have played a pivotal role in vaccine development; however, recent advancements in vaccine delivery systems, such as the development of needle-free drug delivery systems, are anticipated to bolster market development further. For instance, in May 2024, the Serum Institute of India (SII) announced a strategic investment in IntegriMedical, acquiring a 20% stake in the company, to advance Needle-Free Injection System technology. IntegriMedical's Needle-Free Injection Systems (N-FIS) represent a significant advancement in drug delivery and needle-free solutions to deliver vaccines. These developments underscore the growing emphasis on innovative healthcare solutions, which are expected to drive significant advancements in the hepatitis B vaccine market.

Government agencies are working to establish vaccine manufacturing facilities in developing regions to make them better prepared for future health emergencies. Such initiatives are expected to create lucrative opportunities for market development over the forecasted period. For instance, in December 2023, in a bid to assist lower-income nations in recovering from the COVID-19 pandemic and enhancing their readiness for future health crises, the Board of Gavi, the Vaccine Alliance, announced USD 1 billion in support for vaccine manufacturing in Africa. In addition, the board also approved the formation of the African Vaccine Manufacturing Accelerator (AVMA), aimed at promoting sustainable vaccine production across Africa, thus driving the hepatitis B vaccine market.

However, low vaccination rates and limited accessibility in the developing regions, stringent approval processes, and complex cold chain logistics are some of the factors anticipated to hamper the market development over the forecasted period.

Hepatitis B Vaccine Market Trends

Prefilled Syringe Segment is Expected to Develop at a Significant Growth Over the Forecast Period

Mass immunization programs, the growing need to eradicate viral diseases, and the demand for faster administration rates have created lucrative growth opportunities for prefilled syringes. Thus, market players are implementing growth strategies such as collaboration and investment to augment the growing demand for prefilled syringes. For instance, in March 2024, SCHOTT Pharma unveiled plans for a new prefillable syringe manufacturing facility in Wilson, United States. With an investment of USD 371 million, this facility aims to bolster the United States supply chain for syringes pivotal in delivering lifesaving injectables, vaccines, and more. This strategic investment is expected to significantly contribute to the development of the hepatitis B vaccine market by ensuring a reliable supply of high-quality prefillable syringes.

Furthermore, marketing authorization of novel vaccines presents significant growth opportunities as regulatory approvals for innovative vaccines highlight their safety, efficacy, and quality, thereby enhancing trust among healthcare professionals and patients. For example, in February 2023, Dynavax Technologies Corporation announced that the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) had granted marketing authorization for HEPLISAV B. This recombinant, adjuvanted hepatitis B vaccine is approved for active immunization against all known subtypes of the hepatitis B virus in adults aged 18 years and older and is available in prefilled syringes. Such regulatory endorsements are expected to drive the adoption of novel vaccines, presenting significant growth opportunities for the hepatitis B vaccine market during the forecast period.

Contract Development and Manufacturing Organizations (CDMOs) are increasingly supporting vaccine manufacturers by establishing advanced production facilities. These efforts aim to address critical challenges, including scalability, cost optimization, and adherence to regulatory standards. For instance, in November 2024, Pharmaceutics International, Inc. announced a substantial expansion of its prefilled syringe (PFS) capabilities, committing USD 3.6 million to advanced labeling, fill/finish, and automated visual inspection technologies. Thus, CDMOs are playing a vital role in strengthening the vaccine manufacturing ecosystem in turn supporting the hepatitis B vaccine market.

Hence, the above-mentioned factors are expected to strengthen the segment expansion over the forecasted period.

Asia Pacific is Expected to Register the Highest CAGR in the Hepatitis B Vaccine Market

The Asia Pacific region is anticipated to develop at the highest CAGR owing to factors such as the growing prevalence of hepatitis B, foreign investments in routine vaccination programs, and government initiatives, such as national vaccination programs and hepatitis B birth-dose mandates. With the growing infection rate of hepatitis B, the need for widespread immunization is on the rise. For instance, in August 2023, amfAR highlighted that the Asia Pacific region bears a disproportionate burden, accounting for 59% of individuals with chronic HBV, 26% of new infections, and 79% of related fatalities. Additionally, the region contributes to 80% of global liver cancer-related deaths and 59% of deaths associated with liver cirrhosis. These statistics present significant opportunities for market growth in the development and distribution of hepatitis B vaccines.

Foreign governments are significantly contributing to the growth of the hepatitis B vaccine market by providing critical funding, infrastructure support, and enhancing immunization initiatives. For instance, in September 2024, the United States International Development Finance Corporation announced strategic investments in India's private healthcare sector to improve vaccine accessibility. Specifically, a USD 20 million investment was approved for Panacea Biotec Limited to scale up its hexavalent vaccine production capacity to approximately 70 million doses annually. Such investments are expected to drive market development by strengthening manufacturing capabilities and expanding global vaccine distribution networks.

Furthermore, in May 2024, the Government of Japan, in partnership with the Japan International Cooperation Agency (JICA), committed an additional USD 6.9 million to UNICEF. The initiative aims to deliver routine immunization services, protecting 4.1 million women and children from diseases such as Measles, Tuberculosis, Polio, Hepatitis B, and Tetanus. Additionally, in August 2024, UNICEF, in collaboration with the Government of Japan, facilitated the delivery of 60,000 doses of the PENTA-Hib combined vaccine. This vaccine is designed to protect infants during their first year of life from five critical diseases: diphtheria, tetanus, pertussis, Hepatitis B, and Haemophilus influenzae type b (Hib), utilizing a whole-cell pertussis component. These collaborative efforts underscore the growing focus on strengthening immunization programs, which is expected to drive market development.

Therefore, due to the aforementioned factors, the hepatitis B vaccine market in the Asia Pacific region is expected to develop at a significant growth rate over the forecasted period.

Hepatitis B Vaccine Industry Overview

The hepatitis B vaccine market is fragmented in nature due to the presence of several companies operating globally as well as regionally. However, few companies take a significant chunk of the market. The competitive landscape includes an analysis of a few international as well as local companies that hold substantial market share and are well known, including Indian Immunologicals Ltd., GSK plc., Merck & Co., Inc., Dynavax Technologies Corporation, Sanofi, LG Chem, Serum Institute of India Pvt. Ltd., CSL, Hookipa Pharma, Shenzhen Kangtai Biological Products Co., Ltd., and AIM Vaccine, among others.

Hepatitis B Vaccine Market Leaders

Hepatitis B Vaccine Market News

• February 2024: TherVacB, an innovative therapeutic vaccine for chronic hepatitis B, entered its Phase Ia clinical trial. Led by Helmholtz Munich, the trial is being conducted at LMU University Hospital Munich, with the University Medical Center Hamburg-Eppendorf as the sponsor.
• November 2023: HOOKIPA Pharma Inc. announced that The Journal of Infectious Diseases has published preclinical data on HB-400, an investigational therapeutic vaccine for chronic hepatitis B developed in collaboration with Gilead Sciences, Inc. The data highlight HB-400's potential to advance a functional cure for chronic hepatitis B.